Last updated: February 15, 2026
What Are the Criteria for Patentability of Biopharmaceuticals in Lithuania?
Lithuania adheres to the European Patent Convention (EPC), which requires patents to meet three primary criteria: novelty, inventive step, and industrial applicability. Biopharmaceutical inventions must demonstrate that they are new, involve an inventive step beyond existing knowledge, and are capable of industrial use.
Novelty
A biopharmaceutical invention must not have been disclosed before the patent application date. Prior disclosures include publications, public use, or other patent applications.
Inventive Step
The invention must not be obvious to a person skilled in the field. For biopharmaceuticals, this often involves demonstrating that the invention involves a non-obvious technical advancement over existing products, processes, or uses.
Industrial Applicability
The invention must be capable of use in manufacturing or other industrial processes. For biopharmaceuticals, this includes therapeutic, diagnostic, or prophylactic use.
Exclusions
The Lithuanian Patent Office (LPO) excludes certain inventions, notably those involving essentially biological processes for the production of plants or animals, unless the claims specify microbiological or genetic engineering techniques.
How Does Lithuania Address Patent Enforceability for Biopharmaceutical Patents?
Enforceability depends on the patent’s compliance with formal requirements and its resilience against legal challenges.
Compliance Factors
- Proper procedural filing, including complete description, claims, drawings, and abstract.
- Payment of renewal fees at set intervals.
- No late disclosures or amendments that alter the scope of the claims significantly.
Legal Challenges
Biopharmaceutical patents are vulnerable to legal challenges, particularly on grounds such as:
- Lack of novelty or inventive step.
- Insufficient disclosure (non-enabling description).
- Non-patentable subject matter (e.g., certain naturally occurring sequences).
Litigation and Defense
Patent holders can enforce rights through infringement lawsuits in Lithuanian courts, which assess claims based on the scope of granted claims and the facts of alleged infringement.
What Is the Scope of Claims for Biopharmaceutical Patents in Lithuania?
The scope of claims defines the legal protection of the patent. For biopharmaceuticals, claims are typically categorized as compound claims, process claims, use claims, or formulation claims.
Compound Claims
Cover the specific chemical or biological entities, including sequences, structures, and compositions. Such claims must clearly define the invention, often through structural formulas or genetic sequences.
Process Claims
Describe methods of manufacturing or using the biopharmaceutical. Claims may cover synthesis methods, purification processes, or therapeutic use protocols.
Use Claims
Protect specific therapeutic or diagnostic applications. For example, claims may specify the use of a compound for treating a particular disease.
Formulation Claims
Protect specific combinations or compositions, like a drug formulation containing the active biological agent.
Claims should be drafted with precision to avoid ambiguity, and the scope can be limited or broad depending on the strategic intent. Broad claims provide wider protection but face higher scrutiny for infringement and validity.
Policy and Practice Highlights from the Lithuanian Patent Office
- Examines patentability applications based on EPC standards, emphasizing thorough search reports on novelty and inventive step.
- Offers provisional and patent cooperation treaty (PCT) filing routes for international protection.
- Implements strict opposition procedures allowing third-party challenges post-grant.
- Enforces a 20-year patent term from the filing date, subject to payment of annual renewal fees.
Comparison with European Patent Practice
Lithuania aligns closely with EPC norms, but local validation or national phase entry is unavoidable. Patent validity in Lithuania can be challenged via oppositions, similar to other EPC member states, with likelihood of invalidation if claims cover naturally occurring substances without inventive modifications.
Key Takeaways
- Patentability hinges on novelty, inventive step, and industrial applicability, with exclusions for certain biological processes.
- Enforceability depends on procedural compliance and legal robustness against validity challenges.
- Claims should be precisely drafted, balancing breadth and specificity to maximize protection.
- The Lithuanian patent system follows EPC standards, with the ability for third-party opposition after grant.
- Patent protection lasts 20 years from filing, incentivizing prompt filing and renewal.
FAQs
1. Can naturally occurring biological sequences be patented in Lithuania?
Only if they involve inventive modifications or specific uses beyond their natural state.
2. How long does it take to obtain a patent in Lithuania?
Typically 2-3 years from filing, depending on the examination process and application complexity.
3. Are there specific rules for biotech process claims?
Yes. Claims must clearly define the process steps and produce distinct, non-obvious results.
4. What are common grounds for patent opposition in Lithuania?
Lack of novelty, inventive step, or sufficiency of disclosure.
5. How does Lithuania treat "second medical use" claims?
Such claims are protected if they specify a new and inventive therapeutic application of known compounds.
Sources
[1] European Patent Convention (EPC).
[2] Lithuanian Patent Law.
[3] Lithuanian Patent Office Guidelines.
